Jeff Brumfield, chairman and chief executive officer of CDEX, stated, “We are very pleased to welcome Dr. Terrell to our team. He brings to CDEX a unique blend of medical science expertise and progressive medical field business operations background. He will assist in the market application and implementation of CDEX technologies in the medical field and advise on the ongoing development to address other unique unmet needs where the VG4 may be instrumental in detecting foreign related substances.”

Dr. Terrell is currently a corporate medical director for Any Lab Test Now©, the largest direct access medical testing franchise in the United States. Dr. Terrell currently owns and operates multiple medical laboratory testing facilities in the Southwest United States. He earned his Bachelor of Science in Biochemistry from Hardin-Simmons University, graduating Summa Cum Laude and recipient of the Holland Medal of Honor. He earned his MD from the University of Texas at Houston School of Medicine.

“I am excited to join the outstanding team at CDEX. The technology promises to have a global impact in multiple industries. I believe the Valimed G4 will revolutionize parenteral medication safety practices and narcotic diversion control in both healthcare and closely related industries,” stated Jason B. Terrell, M.D., medical director of CDEX. “What’s really exciting is that CDEX’s patented technology can be applied to the analysis of blood, urine, saliva, and other bodily fluids. Preliminary data suggests that the technology provides many advantages over current diagnostics techniques, including the ability to detect lower molecular concentrations, increased sensitivity and specificity with real-time analysis. One of my goals as medical director is to facilitate additional research studies and trials in these areas to expand future product use.”

About CDEX

CDEX develops, manufactures and globally distributes products to the healthcare, safety and security markets. The ValiMed™ product line provides life-saving validation of high-risk medications and pharmacy returned narcotics. The ID2™ product line detects trace amounts of illegal drugs, such as methamphetamine. CDEX expects to advance its patented technologies to serve additional markets in the future where its proprietary products can be launched. To learn more about CDEX please visit: www.cdex-inc.com.

Safe Harbor Statement

Non-historical statements are forward-looking, as defined in federal securities laws, and generally can be identified by words such as “expects,” “plans,” “may,” “believes,” “should,” “intends,” and similar words. These statements pose risks that cannot be accurately predicted. Consequently, results may differ materially from those expressed or implied. Such risks and uncertainties include, without limitation, the effectiveness, profitability and marketability of products, the protection of intellectual property and proprietary information, and other risks detailed periodically in filings with the SEC. There is no obligation to update any forward-looking statements.

“The ACA conference is the largest correctional gatherings of its kind in the world, ACA’s conventions provide attendees with an opportunity to personally interact with key members and technology providers in the correctional industry face-to-face,” stated Jeff Brumfield, chairman and chief executive officer of CDEX. “We will be showcasing our three primary products at the conference including our ValiMed G4 which is applicable for use in verifying illicit substances in the police or correctional lab environment as well as the healthcare setting. We believe the VG4 may have many future applications aside from healthcare and security, and the ACA conference is a great opportunity to showcase its versatility.”

The American Correctional Association is the oldest and largest international correctional association in the world. ACA serves all disciplines within the corrections profession and is dedicated to excellence in every aspect of the field. From professional development and certification to standards and accreditation, from networking and consulting to research and publications, and from conferences and exhibits to technology and testing, ACA is the resource and world-wide authority in corrections.

About CDEX
CDEX develops, manufactures and globally distributes products to the healthcare, safety and security markets. The ValiMed™ product line provides life-saving validation of high-risk medications and pharmacy returned narcotics. The ID2™ product line detects trace amounts of illegal drugs, such as methamphetamine. CDEX expects to advance its patented technologies to serve additional markets in the future where its proprietary products can be launched. To learn more about CDEX please visit: www.cdex-inc.com.

Safe Harbor Statement
Non-historical statements are forward-looking, as defined in federal securities laws, and generally can be identified by words such as “expects,” “plans,” “may,” “believes,” “should,” “intends,” and similar words. These statements pose risks that cannot be accurately predicted. Consequently, results may differ materially from those expressed or implied. Such risks and uncertainties include, without limitation, the effectiveness, profitability and marketability of products, the protection of intellectual property and proprietary information, and other risks detailed periodically in filings with the SEC. There is no obligation to update any forward-looking statements.

Video surveillance provided by the Pima County jail shows a woman reaching into her sock, pulling out crystal meth and then putting it in her mouth attempting to swallow it.

Corrections officers see this through the video monitors approach her and tell her to spit it out. She finally does.

Lt. Sean Stewart who heads Security Services says, “Had she swallowed that it probably would have killed her or at least made her extremely ill.”

On a daily basis, corrections officers like Todd Mattas often find contraband during pat downs.

“We’re the first line of defense as far as preventing any new arrestees from getting injured as well as staff.”

Lt. Stewart says inmates will try anything to smuggle in drugs, weapons, and even cash.

“You’ll find stuff taped to the inner thigh up near the groin area.”

Inmates getting booked have to go thru a metal detector much like the airports, also like the airport a Morpho detection machine.

Sgt. Steve Street says, “It detects any drugs that anybody has on their hands, their clothing any part of their body we decide to test and we do it randomly.”

If the strength reading is 3-point-1 or higher, the inmates are stripped searched.

Lt. Stewart says, “Its just one slippery slope if that stuff gets into your housing unit within a week that whole housing unit could be out of control.”

One more tool to keep the jail as safe and secure as possible.

Not every inmate is stripped search the U-S Supreme court says, officers have to have probable cause to do that.

Original article availible here 

Find Related CDEX Press Releases here

MIAMI | A teenager who lost all four limbs because of a vaccination error has won a $12.6 million award in a lawsuit against the University of Miami medical school.

The Miami jury reached the verdict Friday in the case of Shaniah Rolle of Miramar, the South Florida SunSentinel reported. A judge will likely reduce the award because jurors found Shaniah’s mother partly at fault for not giving her enough medication.

Shaniah had her spleen removed as a newborn 13 years ago. She got a vaccine designed to prevent infections but the medication had expired five months earlier. Shaniah later got an infection that led to amputation of her arms and legs.

University of Miami attorneys had contended Shaniah would have gotten the infection despite the vaccine. An appeal is likely.

Full article available here

Find Related CDEX Press Releases here

TUCSON, AZ–(Marketwire – Dec 6, 2011) – CDEX Inc. (OTCBB: CEXI), a leading developer of chemical detection products using patented technologies for use in healthcare, safety and security markets, today demonstrated its recently launched ValiMed™ G4 multi-component medication and narcotic detection system at the 46th Annual Midyear ASHP Clinical Meeting and Exhibition. The ASHP conference is being held at the New Orleans Ernest N. Morial Convention Center in New Orleans, Louisiana, December 4-8, 2011.

The ValiMed™ G4 will be showcased at booth 247 at the conference.
The ValiMed G4 drug validation system helps healthcare providers ensure patient safety and control costs by reducing medication errors. The patented detection process identifies drug strengths and volume-by-weight in real-time, validating proper dose, diluents and concentration of high-risk compounded medications and treatment solutions. The VG4 device will help healthcare facilities comply with Joint Commission compliance requirements and USP 797 guidelines for compounding sterile preparations (CSPs), and will integrate with electronic medical record (EMR) platforms.

“With the recent launch and commercial production of our ValiMed™ G4 system, we are excited to showcase the system at the ASHP Midyear conference, where a national and international audience of industry professionals will witness the power of our technology. We are the first to commercialize an affordable advanced measuring system, with multi-component capabilities that will enhance and improve the quality of care that pharmacies and clinical professionals provide. The conference should provide an optimum platform for our ValiMed G4 to gain market penetration and build industry buzz for our system. We expect to deliver several units over the next six months as the market interest continues to spread for the VG4,” stated Jeff Brumfield, chairman and chief executive officer of CDEX.

CDEX’s VG4 significantly raises the bar for patient medication safety and pharmaceutical drug loss prevention. The ValiMed G4 provides cutting edge features and benefits over existing systems available in the market. In addition to validating high-risk medications before leaving the clinical or pharmacy environment, the ValiMed G4 will also monitor and discourage the diversion of controlled substances by validating the returned or unused narcotics from patient treatment areas or surgery suites. Other applications for the ValiMed G4 system include counterfeit medication monitoring, regulatory compliance and training of clinical and pharmacy personnel.

The American Society of Health-System Pharmacists (ASHP) Midyear Clinical Meeting and Exhibition is the largest gathering of pharmacists in the world. With its focus on improving patient care, the conference is attended by more than 20,000 pharmacy professionals from 86 countries. For over four decades, the ASHP Midyear Clinical Meeting has provided health-system pharmacy practitioners with a venue for updating their knowledge, networking with colleagues, enhancing their skills, and learning about the latest products and technologies available in the market. For more information about the event please visit: http://www.ashp.org/Midyear2011.

About CDEX
CDEX develops, manufactures and globally distributes products to the healthcare, safety and security markets. The ValiMed™ product line provides life-saving validation of high-risk medications and pharmacy returned narcotics. The ID2™ product line detects trace amounts of illegal drugs, such as methamphetamine. CDEX expects to advance its patented technologies to serve additional markets in the future where its proprietary products can be launched. To learn more about CDEX please visit: www.cdex-inc.com.

Safe Harbor Statement
Non-historical statements are forward-looking, as defined in federal securities laws, and generally can be identified by words such as “expects,” “plans,” “may,” “believes,” “should,” “intends,” and similar words. These statements pose risks that cannot be accurately predicted. Consequently, results may differ materially from those expressed or implied. Such risks and uncertainties include, without limitation, the effectiveness, profitability and marketability of products, the protection of intellectual property and proprietary information, and other risks detailed periodically in filings with the SEC. There is no obligation to update any forward-looking statements.

TUCSON, AZ–(Marketwire – Oct 3, 2011) – CDEX Inc. (OTCBB: CEXI), a leading developer of chemical detection products, using patented technologies for use in healthcare, safety and security markets, announced today the company has shipped the first ValiMed™ G4 drug validation system to a prominent US based global medical technology company. The company intends using the ValiMed G4 as a lab instrument for a research and development project to determine the shelf life of parenteral admixtures with regards to potency over time.

The medical technology company is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. The company serves healthcare institutions, life science researchers, clinical laboratories and pharmaceutical companies worldwide.

“We are honored the ValiMed G4 was chosen to play a critical role in this research project which we believe further validates the breadth of use for our technology. We are excited to ship the first unit of our enhanced ValiMed G4 device to an industry leading medical technology and diagnostic company; this relationship should provide an optimum platform to build our ValiMed G4 market penetration and reputation in the industry. We expect to deliver additional ValiMed G4 units as the market interest continues to spread,” stated Jeff Brumfield, chairman and chief executive officer of CDEX.

The ValiMed G4 drug validation system helps healthcare providers ensure patient safety and control costs by reducing medication errors. The patented detection process identifies drug strengths and volume-by-weight in real-time, validating proper dose, diluents and concentration of high-risk compounded medications and treatment solutions. The VG4 device will help healthcare facilities comply with Joint Commission compliance requirements and USP 797 guidelines for compounding sterile preparations (CSPs), and will integrate with electronic medical record (EMR) platforms.

About CDEX
CDEX develops, manufactures and globally distributes products to the healthcare, safety and security markets. The ValiMed™ product line provides life-saving validation of high-risk medications and pharmacy returned narcotics. The ID2™ product line detects trace amounts of illegal drugs, such as methamphetamine. CDEX expects to advance its patented technologies to serve additional markets in the future where its proprietary products can be launched. To learn more about CDEX please visit: www.cdex-inc.com.

Safe Harbor Statement
Non-historical statements are forward-looking, as defined in federal securities laws, and generally can be identified by words such as “expects,” “plans,” “may,” “believes,” “should,” “intends,” and similar words. These statements pose risks that cannot be accurately predicted. Consequently, results may differ materially from those expressed or implied. Such risks and uncertainties include, without limitation, the effectiveness, profitability and marketability of products, the protection of intellectual property and proprietary information, and other risks detailed periodically in filings with the SEC. There is no obligation to update any forward-looking statements.

TUCSON, AZ–(Marketwire – Sep 27, 2011) – CDEX Inc. (OTCBB: CEXI), a leading developer of chemical detection products, using patented technologies for use in healthcare, safety and security markets, will demonstrate the capabilities of the ValiMed™ G4 drug validation system at the 2011 Health Connect Partners Fall Hospital Pharmacy Conference. The conference is taking place September 26-28, 2011 at the Arizona Biltmore in Phoenix, Ariz.

The Hospital Pharmacy Conference connects healthcare providers and suppliers through a selection of educational meetings and conferences. The conference is known for its large scale Reverse Expo with hospital pharmacy-hosted booths. Suppliers have a unique opportunity to gain a deeper understanding of their clients’ needs and preferences.

Senior members of the CDEX team will be attending the semi-annual event which connects healthcare industry leaders and provides education on the current state of hospital pharmacy business and legislation.

“Attending the Health Connect Partners conference is a vital part of our continued efforts to market our new ValiMed G4 directly to the key decision makers in the healthcare pharmacy system. The conference provides an optimum environment to build and enhance relationships with top hospital and health system pharmacy executives from across the US. The event is a great platform to launch our VG4 and further build our pipeline of interested agencies. We expect to deliver our first VG4 unit ahead of schedule,” stated Jeff Brumfield, chairman and chief executive officer of CDEX.

The ValiMed G4 drug validation system helps healthcare providers ensure patient safety and control costs by reducing medication errors. The patented detection process identifies drug strengths and volume-by-weight in real-time, validating proper dose, diluents and concentration of high-risk compounded medications and treatment solutions. The VG4 device will help healthcare facilities comply with Joint Commission compliance requirements and USP 797 guidelines for compounding sterile preparations (CSPs), and will integrate with electronic medical record (EMR) platforms.

About CDEX
CDEX develops, manufactures and globally distributes products to the healthcare, safety and security markets. The ValiMed™ product line provides life-saving validation of high-risk medications and pharmacy returned narcotics. The ID2™ product line detects trace amounts of illegal drugs, such as methamphetamine. CDEX expects to advance its patented technologies to serve additional markets in the future where its proprietary products can be launched. To learn more about CDEX please visit: www.cdex-inc.com.

Safe Harbor Statement
Non-historical statements are forward-looking, as defined in federal securities laws, and generally can be identified by words such as “expects,” “plans,” “may,” “believes,” “should,” “intends,” and similar words. These statements pose risks that cannot be accurately predicted. Consequently, results may differ materially from those expressed or implied. Such risks and uncertainties include, without limitation, the effectiveness, profitability and marketability of products, the protection of intellectual property and proprietary information, and other risks detailed periodically in filings with the SEC. There is no obligation to update any forward-looking statements.

TUCSON, AZ–(Marketwire – Sep 16, 2011) – CDEX Inc. (OTCBB: CEXI), a leading developer of chemical detection products, using its patented technologies, for use in healthcare and security markets, today reported financial results for the third quarter ended July 31, 2011.

“We continue to make strides toward launching our Valimed G4 Medication Validation system and expect to reach full commercialization over the next 60 days. Our target pipeline of hospitals and healthcare agencies continues to build as our marketing efforts drive interest nationwide. We are confident we will begin placing units over the remainder of this year, while building momentum to expand market penetration in 2012. We have been invited to present at several industry events over the next two quarters which should generate significant leads to expand our pipeline and position us for growth as we enter the 2012 calendar year,” stated Jeff Brumfield, chairman and chief executive officer of CDEX. “Although our security division has not accelerated sales as expected, we believe CDEX is ideally situated to support increased demand for our ID2 product line when municipal and state government budgets recover over the next 12 months. Overall we are very pleased with our progress as a company, we continue to monitor or costs as evidenced by our significant reduction in spending and debt, while generating positive cash flow from operations. We believe our continued progress towards the launch of the Valimed G4 and increasing market interest in the ID2 product line positions CDEX for significant growth as we push towards 2012.”

Third Quarter 2011 Financial Results
– Total revenues for the third quarter ended July 31, 2011 were approximately $232,000, a 15% increase compared to $202,000 for the third quarter of 2010. The $30,000 increase was primarily attributable to the increase in the sales of ID2 Meth Scanner.

– Total operating expenses for the quarter ended July 31, 2011 were approximately $240,000, a 55% decrease compared with $533,000 for the same period 2010. The $293,000 decrease was primarily attributable to decreases in consulting, professional and legal expenses, travel, marketing and general operating expenses partially offset by increases in non-cash share-based expenses, research and development, employee compensation. The increase in research and development is primarily based on the increased focus on the further advancement of the Pocket ID2 detection device and Valimed G4 Medication Validation system.

– Net loss for the quarter ended July 31, 2011 was approximately $258,000, or $(0.00) per share, based on 95,291,618 basic weighted common shares outstanding compared with a net loss of $537,000, or $(0.01) per share based on 65,239,634 basic weighted common shares outstanding, for the same period in 2010.

– The Company’s cash position increased to approximately $130,000 for the period ending July 31, 2011 compared with $117,000 for the previous quarter ended April 30, 2011. At July 31, 2011, the Company had $524,000 in total assets compared to $491,000 from the previous quarter ended April 30, 2011. Total liabilities were reduced by $1.1 million to $2.7 million for the period ending July 31, 2011 compared with $3.8 million the previous quarter end April 30, 2011 and reduced by $1.4 million from $4.1 million for yearend October 31, 2010.

– The company generated positive cash flow from operation of $37,000 for the quarter ended July 31, 2011 vs negative cash flow of $68,000 for the same period the previous year.

Recent Developments
– Announced the Sale and Shipment of Ten ID2 Meth Scanners: The Company sold and shipped 10 units of the ID2 Meth Scanners to the Northeastern Colorado Association of Governments and Healing Tree Addiction Treatment Solutions, Inc. The order represented the largest direct sale and shipment of ID2 Meth Scanners by CDEX to date.

– CDEX Presented the Pocket ID2 at the 2011 NHTSA Bi-Regional Law Enforcement Training Summit: Company representatives presented the Pocket ID2™ device at the 2011 NHTSA Bi-Regional Law Enforcement Training Summit. The training summit, which took place June 21-23, 2011 in Louisville, KY, brought together law enforcement divisions from the Southeast, Mid-Atlantic and Mid-West regions of the US.

– Company tapped Public Safety Industry Veteran as Director of Outside Sales: Public safety industry veteran John McConnell joined the CDEX team as Director of Outside Sales. Mr. McConnell’s professional background spans more than 20 years as an advisor and senior executive with several leading security and technology companies.

About CDEX
CDEX develops, manufactures and globally distributes products to the healthcare and security markets. The ValiMed™ product line provides life-saving validation of high-risk medications and pharmacy returned narcotics. The ID²™ product line detects trace amounts of illegal drugs, such as methamphetamine. CDEX expects to advance its patented technologies to serve additional markets in the future where its proprietary products can be launched. To learn more about CDEX please visit: www.cdex-inc.com.

Safe Harbor Statement
Non-historical statements are forward-looking, as defined in federal securities laws, and generally can be identified by words such as “expects,” “plans,” “may,” “believes,” “should,” “intends,” and similar words. These statements pose risks that cannot be accurately predicted. Consequently, results may differ materially from those expressed or implied. Such risks and uncertainties include, without limitation, the effectiveness, profitability and marketability of products, the protection of intellectual property and proprietary information, and other risks detailed periodically in filings with the SEC. There is no obligation to update any forward-looking statements.